Shanghai Jahwa(SH:600315) Goldman Sachs·2026-01-22 07:45Investment Rating - The report upgrades MGP to Buy from Neutral, highlighting its sustainable growth and resilient margins in the premium beauty market [10] - Giant Biogene is rated Buy, with expectations of a gradual recovery in sales and strong long-term growth potential [16] - Shanghai Jahwa is also rated Buy, indicating a turnaround in its skincare business and solid growth prospects [22] Core Insights - The China cosmetics industry is expected to see sustained momentum driven by higher-quality channels and a focus on new product cycles [3] - The government's anti-involution measures are likely to increase traffic acquisition costs, impacting sales on platforms like Douyin [3] - There is a shift towards reliability and brand trust in consumer preferences, prompting companies to innovate and upgrade their product offerings [4] Summary by Sections Key Trends - Higher-quality channels are expected to maintain momentum, particularly on Tmall, supported by government measures [3] - The product landscape is shifting towards proven efficacy and brand trust, with companies innovating to create new value propositions [4] Company-Specific Insights - MGP is positioned for sustainable growth with a projected 34%/38% sales/NI CAGR from 2021-2025, and 23%/22% from 2025-2027 [10][11] - Giant Biogene anticipates a sales decline in the short term but expects recovery driven by its leading brand position and product pipeline [16] - Shanghai Jahwa is experiencing strong growth in its key brands, with a projected CAGR of 2%/34% for its personal care/cosmetics segment from 2025-2027 [22] Valuation Methodology - MGP's target price is set at HK$105 based on a 28x 2027E P/E, reflecting its high growth profile [12] - Giant Biogene's target price is HK$46, based on a 22x 2027E P/E, indicating a recovery in its sales profile [17] - Shanghai Jahwa's target price is RMB 28, based on a 30x 2027E P/E, reflecting its improving sales and net profit profile [23]